Shenzhen City recently issued the “List of Key Tasks for Optimizing the Business Environment Reform in Shenzhen City in 2020” as a specific measure to fully implement the spirit of the General Secretary’s important instructions on taking the lead in increasing the intensity of business environment reform, striving to create a first-class business environment, and continuously solving key issues of concern to enterprises and citizens.
Shenzhen has listed optimizing the business environment as the “No. 1 reform project”,On May 20, the Municipal Development and Reform Commission held the first meeting of the Shenzhen Business Environment Optimization Advisory and Supervision Committee (First Session) at the Civic Center and announced the establishment of the committee. Dr. Hu Xiang of Beike Biotech was hired as the deputy chairman of the committee.
Guo Yuehua, deputy director of the Municipal Development and Reform Commission, attended the meeting and issued letters of appointment to the employed members. Deputy Director Guo Yuehua said that the business environment is a sign that various countries and regions attach great importance to in their economic development. As a pioneering demonstration zone for socialism with Chinese characteristics, Shenzhen must be at the forefront in optimizing the business environment and must be a pioneer, a model, and a benchmark. This is also an important mission of the Optimizing Business Environment Advisory and Supervision Committee.
The appointed members of the Shenzhen Business Environment Optimization Advisory and Supervision Committee have made outstanding contributions and are highly representative in all walks of life. Beike Biotech has a top stem cell research team and cutting-edge cell storage and preparation technology. The innovative industrial development model of “comprehensive cell bank + regional cell intelligent manufacturing center + cell quality testing platform” provides an innovative public technology platform and infrastructure for the clinical transformation of cell therapy technology. It also lays a data foundation for the future development layout of artificial intelligence + biomedicine. In January 2020, Beike Biotech’s research result “Key technological innovation and clinical application of allogeneic mesenchymal stem cells in the treatment of refractory lupus erythematosus” won the 2019 National Technology Invention Award.
During this fight against the epidemic, Beike Biotech’s participation in the fight against COVID-19 was approved by the Guangdong Provincial Department of Science and Technology for the “Technological Emergency Response Project for the Prevention and Control of Novel Coronavirus Infection” and the Kunming Municipal Science and Technology Bureau for the “Special Technological Prevention and Control of New Coronavirus Infection and Pneumonia” project, contributing to the fight against the epidemic.
